Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| YMAT | PRESS-RELEASE | mixed | 5/10 | J-Star signed a non-binding MOU with White Group to facilitate a $100M investment in its planned solid-state battery fac | May 8, 2026 |
| UG | PRESS-RELEASE | bullish | 6/10 | United-Guardian reported Q1 2026 revenue of $2.87M (+16% YoY) and EPS of $0.18 (+50% YoY), driven by 24% growth in pharm | May 8, 2026 |
| DRTS | PRESS-RELEASE | bullish | 7/10 | Alpha Tau completed enrollment in its ReSTART pivotal trial (88 patients) for Alpha DaRT in recurrent cutaneous squamous | May 8, 2026 |
| EWCZ | PRESS-RELEASE | neutral | 8/10 | European Wax Center has been taken private by General Atlantic in an all-cash transaction valued at approximately $640 m | May 8, 2026 |
| ALLR | PRESS-RELEASE | neutral | 2/10 | Allarity Therapeutics CEO Thomas Jensen will present at Precision Medicine Forum Europe 2026 on May 11, discussing steno | May 8, 2026 |
| GENC | PRESS-RELEASE | mixed | 5/10 | Gencor reported Q2 2026 revenue of $33.8M, down 11.5% YoY and below consensus of $36.5M, while EPS of $0.41 matched esti | May 8, 2026 |
| ABR | PRESS-RELEASE | bearish | 7/10 | Arbor Realty Trust reported Q1 2026 GAAP net income of $0.6M ($0.00/diluted share), a sharp decline from $30.4M ($0.16) | May 8, 2026 |
| SWAG | PRESS-RELEASE | neutral | 1/10 | Stran & Company, Inc. announced it will host a conference call on May 13, 2026 to discuss its Q1 2026 results. | May 8, 2026 |
| PRE | PRESS-RELEASE | neutral | 1/10 | Prenetics Global Limited announced it will report its Q1 2026 results on May 14, 2026. | May 8, 2026 |
| CGON | PRESS-RELEASE | neutral | 5/10 | CG Oncology reported Q1 2026 results with a net loss of $0.71 per share, slightly wider than the $0.45 loss a year ago, | May 8, 2026 |
| AEHL | PRESS-RELEASE | mixed | 4/10 | Antelope Enterprise Holdings announced a $95,000 share repurchase program funded by 50% of realized gains from its Bitco | May 8, 2026 |
| CMDB | PRESS-RELEASE | neutral | 1/10 | Costamare Bulkers Holdings Limited announced it will report its Q1 2026 results on May 13, 2026. | May 8, 2026 |
| CCHH | PRESS-RELEASE | neutral | 3/10 | CCH Holdings announced the effectiveness of its dual-class share structure, with Class B shares holding 50 votes each ve | May 8, 2026 |
| HUMA | PRESS-RELEASE | neutral | 1/10 | Humacyte, Inc announced it will report its Q1 2026 results on May 13, 2026. | May 8, 2026 |
| ALXO | PRESS-RELEASE | bearish | 6/10 | ALX Oncology reported Q1 2026 GAAP EPS of -$0.17, significantly missing the consensus estimate of -$0.16 (a -6.25% miss) | May 8, 2026 |
| ALMR | PRESS-RELEASE | bullish | 7/10 | Alamar Biosciences reported Q1 2026 revenue of $26.0M, up 99% YoY from $13.1M, driven by 178% consumable growth and 78% | May 8, 2026 |
| TRAW | PRESS-RELEASE | neutral | 4/10 | Traws Pharma announced plans to develop clinical candidates for hantavirus treatment following a recent outbreak linked | May 8, 2026 |
| PSTV | PRESS-RELEASE | bullish | 6/10 | Plus Therapeutics presented a plenary session at the 2026 AANS Annual Meeting highlighting Phase 1 ReSPECT-LM data for R | May 8, 2026 |
| PAA | PRESS-RELEASE | mixed | 6/10 | PAA reported Q1 2026 adjusted net income per common unit of $0.39, in line with the year-ago period but below the consen | May 8, 2026 |
| HYPD | PRESS-RELEASE | bearish | 6/10 | Hyperion DeFi closed a public offering of 2,777,778 shares at $3.60 per share, raising approximately $10.0 million in gr | May 8, 2026 |
| BOLD | PRESS-RELEASE | bearish | 6/10 | Boundless Bio reported Q1 2026 net loss of $13.6M ($0.60/share), wider than the consensus estimate of $0.56 loss per sha | May 8, 2026 |
| TVRD | PRESS-RELEASE | neutral | 4/10 | Tvardi Therapeutics reported Q1 2026 EPS of -$0.73, missing consensus of -$0.72 by 1.4% (in-line), with no revenue. The | May 8, 2026 |
| WULF | PRESS-RELEASE | bearish | 7/10 | TeraWulf reported Q1 2026 revenue of $34.0M (in line with $32.6M consensus) but GAAP EPS of -$1.01, far worse than the - | May 8, 2026 |
| LNSR | PRESS-RELEASE | bearish | 7/10 | LENSAR reported Q1 2026 revenue of $13.4M, down 5% YoY, and GAAP net income of $36.3M ($1.56 basic EPS) driven by $23.9M | May 8, 2026 |
| ULBI | PRESS-RELEASE | bearish | 7/10 | Ultralife reported a weak Q1 2026 with revenue down 6.5% YoY to $47.4M and a GAAP net loss of ($0.03)/share vs $0.11 pro | May 8, 2026 |
| AMCX | PRESS-RELEASE | bearish | 7/10 | AMC Global Media reported Q1 2026 GAAP EPS of -$0.43 (vs consensus $0.21, a miss) and revenue of $542M (vs $540.3M conse | May 8, 2026 |
| TMCI | PRESS-RELEASE | bearish | 7/10 | Treace Medical Concepts reported Q1 2026 revenue of $47.2M (down 10% YoY) and a GAAP net loss of $(0.28)/share, beating | May 8, 2026 |
| ANIP | PRESS-RELEASE | bullish | 8/10 | ANI Pharmaceuticals reported Q1 2026 adjusted non-GAAP diluted EPS of $2.05, beating the $1.30 consensus by 57.7%, on re | May 8, 2026 |
| BBUC | PRESS-RELEASE | mixed | 5/10 | Brookfield Business Corporation reported Q1 2026 net income attributable to shareholders of $40M ($0.19 per share), down | May 8, 2026 |
| BAM | PRESS-RELEASE | bullish | 7/10 | Brookfield Asset Management reported Q1 2026 distributable earnings per share of $0.43, beating the $0.42 consensus by 2 | May 8, 2026 |